On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...

A new combination treatment may offer a promising option for patients with relapsed or refractory cutaneous T-cell lymphoma ...

News that you have relapsed/refractory multiple myeloma can trigger a cascade of emotions. Educate yourself about treatment and self-management to help.

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition ...

And symptoms increase as the disease becomes relapsed and refractory. These include: Fatigue. When your bone marrow doesn’t make enough red blood cells, you may feel tired all the time.

"Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.